A Phase I Trial of VNP40101M [laromustine], a Novel Alkylating Agent, Administered Weekly for Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs Laromustine (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 02 Jan 2008 Status changed from in progress to completed.
- 18 Sep 2005 New trial record.